[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
August 8, 1953


Author Affiliations


From the Department of Surgery, Columbia Hospital.

JAMA. 1953;152(15):1429-1430. doi:10.1001/jama.1953.63690150003009b

The use of streptokinase and streptodornase recently has gained much popularity, especially in the treatment of hemothorax in which clotted blood and fibrinous and purulent accumulations are present. Usually these enzymes are injected intrapleurally in the form of a freshly made sodium chloride solution. They cause a rapid dissolving of the blood clots and fibrinous exudates, thus facilitating removal of the material by aspiration.

Since streptokinase and streptodornase are antigenic, the possibility of the occurrence of dangerous anaphylactoid reactions, especially when the enzymes are injected intrapleurally, should be considered and watched for. Until recently, no severe reactions have been reported, except that in a case in which the outcome was fatal when the drug was injected intrathecally. Literature accompanying the commercial preparations of the product state that allergic reactions have been minimal but nevertheless should be watched for. Carr and Robbins,1 in a series in which they used combined

First Page Preview View Large
First page PDF preview
First page PDF preview